Targeted Genotypes: 1 – 6
Treatment Description: Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is a combination of sofosbuvir, a nucleotide NS5B polymerase inhibitor, velpatasvir, a NS5A inhibitor, and voxilaprevir, a NS3/4A protease inhibitor.
Daily Dose: 1 pill
Each tablet is available as a fixed-dose combination tablet containing 400 mg of sofosbuvir, 100 mg of velpatasvir and 100 mg of voxilaprevir. Vosevi should be taken with food, but it does not matter what kind of food.
Length of Treatment:
|For the treatment of chronic hepatitis C genotype 1-6 in patients:||# of Weeks|
|NS5A Inhibitor treatment-experienced with or without cirrhosis||12|
|Treatment regimens for genotype 1, 2, 3 or 4 DAA experienced adult patients with:|
|Non-NS5A Inhibitor, sofosbuvir-containing regimen for those who are treatment-experienced with or without cirrhosis||12|
Common Side Effects:
- Difficulty sleeping
- Lack of energy and strength
BC’s PharmaCare Eligibility for Vosevi
Vosevi is a limited coverage drug. To qualify for treatment coverage a patient must have already tried treatment with DAAs, be treatment experienced with DAAs, and have all of the following:
- Treatment prescribed by a hepatologist, a gastroenterologist, an infectious disease specialist or other physicians experienced with treating hepatitis C
- Lab-confirmed hepatitis C genotype 1, 2, 3, 4, 5, or 6
- Not currently taking another hep C treatment
- Detectable levels of hep C in the last 12 months
- A liver fibrosis stage F0
Talk to your healthcare provider for more information or to start the treatment process.
Gilead’s Momentum Patient Assistance Program
Canadians prescribed Vosevi can request to be enrolled in the Gilead Momentum Program. For more information, contact your doctor, nurse, or call the Gilead Momentum Program at: 1-866-207-4267.